TY - JOUR
T1 - Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
AU - IMPACC Network
AU - Diray-Arce, Joann
AU - Fourati, Slim
AU - Doni Jayavelu, Naresh
AU - Patel, Ravi
AU - Maguire, Cole
AU - Chang, Ana C.
AU - Dandekar, Ravi
AU - Qi, Jingjing
AU - Lee, Brian H.
AU - van Zalm, Patrick
AU - Schroeder, Andrew
AU - Chen, Ernie
AU - Konstorum, Anna
AU - Brito, Anderson
AU - Gygi, Jeremy P.
AU - Kho, Alvin
AU - Chen, Jing
AU - Pawar, Shrikant
AU - Gonzalez-Reiche, Ana Silvia
AU - Hoch, Annmarie
AU - Milliren, Carly E.
AU - Overton, James A.
AU - Westendorf, Kerstin
AU - Abraham, James
AU - Adkisson, Michael
AU - Albert, Marisa
AU - Altamirano Torres, Luz
AU - Alvarenga, Bonny
AU - Anderson, Matthew L.
AU - Anderson, Evan J.
AU - Arnett, Azlann
AU - Asashima, Hiromitsu
AU - Atkinson, Mark A.
AU - Baden, Lindsey R.
AU - Barton, Brenda
AU - Beach, Katherine
AU - Beagle, Elizabeth
AU - Becker, Patrice M.
AU - Bell, Matthew R.
AU - Bernui, Mariana
AU - Bime, Chris
AU - Boddapati Kumar, Arun
AU - Booth, Leland J.
AU - Kelly, Geoffrey
AU - Mulder, Lubbertus C.F.
AU - Rahman, Adeeb H.
AU - Simon, Viviana
AU - Kim-Schulze, Seunghee
AU - Krammer, Florian
AU - van Bakel, Harm
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/6/20
Y1 - 2023/6/20
N2 - The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1–3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72 h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28 days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.
AB - The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1–3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72 h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28 days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.
KW - COVID-19
KW - SARS-CoV-2
KW - immunophenotyping
KW - longitudinal modeling
KW - multi-omics
KW - systems immunology
UR - http://www.scopus.com/inward/record.url?scp=85162133285&partnerID=8YFLogxK
U2 - 10.1016/j.xcrm.2023.101079
DO - 10.1016/j.xcrm.2023.101079
M3 - Article
C2 - 37327781
AN - SCOPUS:85162133285
SN - 2666-3791
VL - 4
JO - Cell Reports Medicine
JF - Cell Reports Medicine
IS - 6
M1 - 101079
ER -